Last updated: 15 August 2024 at 5:27pm EST

Gary Lyons Net Worth




The estimated Net Worth of Gary A Lyons is at least $29.1 Million dollars as of 13 August 2024. Mr. Lyons owns over 11,570 units of Neurocrine Biosciences stock worth over $15,866,047 and over the last 22 years he sold NBIX stock worth over $12,764,369. In addition, he makes $507,100 as Independent Director at Neurocrine Biosciences.

Mr. Lyons NBIX stock SEC Form 4 insiders trading

Gary has made over 41 trades of the Neurocrine Biosciences stock since 2010, according to the Form 4 filled with the SEC. Most recently he exercised 11,570 units of NBIX stock worth $494,733 on 13 August 2024.

The largest trade he's ever made was exercising 85,000 units of Neurocrine Biosciences stock on 7 March 2014 worth over $933,300. On average, Gary trades about 3,198 units every 36 days since 2003. As of 13 August 2024 he still owns at least 130,617 units of Neurocrine Biosciences stock.

You can see the complete history of Mr. Lyons stock trades at the bottom of the page.





Gary Lyons biography

Gary A. Lyons serves as Independent Director of the Company. He has served on the Board of Directors since joining Neurocrine Biosciences in February 1993. Mr. Lyons served as the President and Chief Executive Officer of the Company from February 1993 through January 2008. Prior to joining the Company, Mr. Lyons held a number of senior management positions at Genentech, Inc., including Vice President of Business Development and Vice President of Sales. Mr. Lyons is currently the Chairman of the Board of Directors for each of Rigel Pharmaceuticals, Inc., a biotechnology company focused on developing drugs for the treatment of inflammatory/autoimmune and metabolic diseases, and Retrophin, an ultra-orphan disease commercial stage company. Mr. Lyons is a member of the Board of Directors of Brickell Biotech, Inc., a biotechnology company focused on dermatology, and Novus Therapeutics, Inc., a biotechnology company focused on ear, nose and throat therapies. Mr. Lyons was previously a director of Neurogesx, Cytori Therapeutics, and Facet Biotech Corporation. Mr. Lyons holds a B.S. in marine biology from the University of New Hampshire and an M.B.A. from Northwestern University’s J.L. Kellogg Graduate School of Management. The continued service of Mr. Lyons on the Company’s Board of Directors is based on Mr. Lyons’ extensive business development and corporate governance experience and, as the Company’s former Chief Executive Officer, his in-depth understanding of the Company’s product candidates, management and culture. With this history with the Company and management, Mr. Lyons brings a unique perspective and point of view to the Company’s Board of Directors.

What is the salary of Gary Lyons?

As the Independent Director of Neurocrine Biosciences, the total compensation of Gary Lyons at Neurocrine Biosciences is $507,100. There are 17 executives at Neurocrine Biosciences getting paid more, with Kevin Gorman having the highest compensation of $9,450,830.



How old is Gary Lyons?

Gary Lyons is 68, he's been the Independent Director of Neurocrine Biosciences since 2008. There are 1 older and 22 younger executives at Neurocrine Biosciences. The oldest executive at Neurocrine Biosciences, Inc. is William Rastetter, 72, who is the Independent Chairman of the Board.

What's Gary Lyons's mailing address?

Gary's mailing address filed with the SEC is 12780, El Camino Real, San Diego, San Diego County, California, 92014, United States.

Insiders trading at Neurocrine Biosciences

Over the last 22 years, insiders at Neurocrine Biosciences have traded over $159,913,426 worth of Neurocrine Biosciences stock and bought 103,400 units worth $589,660 . The most active insiders traders include Partners L P/Ilbiotechnolog..., Partners L P/Ilbiotechnolog..., and Richard F Pops. On average, Neurocrine Biosciences executives and independent directors trade stock every 8 days with the average trade being worth of $1,567,813. The most recent stock trade was executed by William H Rastetter on 15 August 2024, trading 14,250 units of NBIX stock currently worth $2,090,333.



What does Neurocrine Biosciences do?

neurocrine biosciences, inc of san diego is a product based biopharmaceutical company focusing on the development and commercialization of innovative pharmaceutical products to treat unmet medical needs. the company's research and development efforts are focused on neurological and endocrine diseases and disorders. our product candidates address some of the largest pharmaceutical markets in the world including endometriosis, irritable bowel syndrome, anxiety, depression, pain, diabetes, insomnia, and other neurological and endocrine related diseases and disorders



What does Neurocrine Biosciences's logo look like?

Neurocrine Biosciences, Inc. logo

Complete history of Mr. Lyons stock trades at Neurocrine Biosciences, Novus Therapeutics Inc, PDL Biopharma Inc, Retrophin, Rigel Pharmaceuticals, and Brickell Biotech Inc

Date
#
Company
Insider
Trans.
Transaction
Shares Price per share Total value Shares after Source
13 Aug 2024 Gary A Lyons
Director
Option 11,570 $42.76 $494,733
13 Aug 2024
130,617
16 Jul 2024 Gary A Lyons
Director
Option 930 $42.76 $39,767
16 Jul 2024
119,977
17 May 2024 Gary A Lyons
Director
Option 2,100 $142.29 $298,809
17 May 2024
119,047
14 May 2024 Gary A Lyons
Director
Option 12,500 $42.76 $534,500
14 May 2024
129,447
22 Dec 2023 Gary A Lyons
Director
Sale 10,000 $130.04 $1,300,400
22 Dec 2023
193,697
1 Dec 2023 Gary A Lyons
Director
Option 5,000 $12.98 $64,900
1 Dec 2023
208,697
12 Sep 2023 Gary A Lyons
Director
Option 5,000 $12.98 $64,900
12 Sep 2023
208,697
1 Sep 2023 Gary A Lyons
Director
Option 5,000 $12.98 $64,900
1 Sep 2023
208,697
31 Oct 2022 Gary A Lyons
Director
Option 15,000 $12.71 $190,650
31 Oct 2022
218,697
4 Oct 2022 Gary A Lyons
Director
Sale 5,000 $110.54 $552,700
4 Oct 2022
203,697
25 Apr 2022 Gary A Lyons
Director
Option 15,000 $6.66 $99,900
25 Apr 2022
223,697
7 Oct 2021 Gary A Lyons
Director
Sale 5,000 $105.06 $525,300
7 Oct 2021
208,697
10 Jun 2021 Gary A Lyons
Director
Sale 10,000 $100.27 $1,002,700
10 Jun 2021
213,697
25 Jan 2021 Gary A Lyons
Director
Sale 2,000 $120.02 $240,040
25 Jan 2021
223,697
8 Nov 2019 Gary A Lyons
Director
Sale 5,000 $110.00 $550,000
8 Nov 2019
225,697
1 Nov 2019 Gary A Lyons
Director
Sale 5,000 $100.22 $501,100
1 Nov 2019
230,697
30 Jul 2019 Gary A Lyons
Director
Sale 10,000 $92.07 $920,700
30 Jul 2019
235,697
2 Nov 2018 Gary A Lyons
Director
Sale 15,000 $114.41 $1,716,150
2 Nov 2018
245,697
13 Jun 2018 Gary A Lyons
Director
Sale 15,000 $99.24 $1,488,600
13 Jun 2018
260,697
3 Apr 2018 Gary A Lyons
Director
Option 15,000 $7.05 $105,750
3 Apr 2018
277,066
15 Feb 2018 Gary A Lyons
Director
Sale 5,000 $84.67 $423,350
15 Feb 2018
262,066
5 Feb 2018 Gary A Lyons
Director
Sale 5,000 $83.08 $415,400
5 Feb 2018
267,066
1 Dec 2017 Gary A Lyons
Director
Sale 10,000 $72.92 $729,200
1 Dec 2017
272,066
14 Feb 2017 Gary A Lyons
Director
Option 15,000 $3.40 $51,000
14 Feb 2017
282,066
6 May 2016 Gary A Lyons
Director
Option 15,000 $3.07 $46,050
6 May 2016
267,066
18 Sep 2015 Gary A Lyons
Director
Sale 15,000 $54.89 $823,350
18 Sep 2015
252,066
24 Mar 2015 Gary A Lyons
Director
Sale 30,000 $41.53 $1,245,900
24 Mar 2015
267,066
10 Feb 2015 Gary A Lyons
Director
Option 7,500 $4.76 $35,700
10 Feb 2015
298,062
20 Jan 2015 Gary A Lyons
Director
Option 7,500 $4.76 $35,700
20 Jan 2015
291,664
15 Sep 2014 Gary A Lyons
Director
Sale 20,000 $15.66 $313,200
15 Sep 2014
284,164
7 Mar 2014 Gary A Lyons
Director
Option 85,000 $10.98 $933,300
7 Mar 2014
357,495
31 Aug 2020 Gary A Lyons
Director
Option 692 $0.94 $650
31 Aug 2020
21,772
31 Jul 2020 Gary A Lyons
Director
Option 692 $0.92 $637
31 Jul 2020
21,426
30 Jun 2020 Gary A Lyons
Director
Option 691 $1.00 $691
30 Jun 2020
21,080
14 Feb 2020 Gary A Lyons
Director
Option 6,258 $1.16 $7,259
14 Feb 2020
3,474


Neurocrine Biosciences executives and stock owners

Neurocrine Biosciences executives and other stock owners filed with the SEC include: